Celiac Disease
Authors:
Open Access
- 1 November 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (11) , 2023-2028
Abstract
Background: Selective deamidation of glutamine residues by tissue transglutaminase (tTG) turns gliadin peptides into stronger activators of T cells from celiac disease (CD) patients. We examined the possibility that these modified peptides could be more specific epitopes for circulating antibodies than are native peptides. Methods: Two native synthetic peptides and their respective modified sequences were used as antigens for ELISA assays: peptide-1, with residues 56–75 of α-type gliadin; and peptide-2, with residues 134–153 of γ-type gliadin. We examined 40 CD patients [31 not being treated with a gluten-free diet (GFD) and 9 being treated with a GFD] and 30 non-CD patients. Results: An enhanced response against deamidated peptides was observed in 4 (IgA) and 22 (IgG) of 31 untreated CD patients for peptide-1 and in 25 (IgA) and 29 (IgG) patients for peptide-2. Higher anti-gliadin antibody and anti-tTG IgA concentrations correlated with increased IgA reactivity to modified peptides. Among the nine treated CD patients, eight also displayed an improved IgG signal for the deamidated sequence. Deamidation of peptides did not increase the reactivity of non-CD sera. Conclusions: Selective deamidation specifically increases circulating antibody recognition of gliadin peptides in CD patients. This suggests that deamidated gliadin peptides are more specific CD B-cell epitopes than native peptides; this finding may be relevant for designing improved diagnostic tests.Keywords
This publication has 15 references indexed in Scilit:
- B cell epitopes of gliadinClinical and Experimental Immunology, 2000
- Molecular Basis of Celiac DiseaseAnnual Review of Immunology, 2000
- In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitopeNature Medicine, 2000
- Identification of tissue transglutaminase as the autoantigen of celiac diseaseNature Medicine, 1997
- Is there IgA of gut mucosal origin in the serum of HIV1 infected patients?Gut, 1994
- Comparison of the intestinal and serum antibody response in patients with dermatitis herpetiformisClinical Immunology and Immunopathology, 1992
- Gluten, major histocompatibility complex, and the small intestineGastroenterology, 1992
- Human serum transglutaminase and coeliac disease: correlation between serum and mucosal activity in an experimental model of rat small bowel enteropathy.Gut, 1989
- Immunoglobulin A (IgA): Molecular and Cellular Interactions Involved in IgA Biosynthesis and Immune Response1987
- Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac diseaseClinical Science, 1985